Clearmind Medicine (CMND) said Friday its alcohol use disorder oral drug candidate CMND-100 has reached the U.S., moving the drug closer to a planned phase 1/2a trial.
The trial will evaluate the drug's safety and efficacy in lowering alcohol consumption.
The study will be carried out at the Yale School of Medicine's Department of Psychiatry and Johns Hopkins University School of Medicine.
The Israeli trial will be conducted at IMCA (Israel Medical Center for Addiction) in Israel.
Price: 1.18, Change: +0.01, Percent Change: +0.43
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。